1. Human Papilloma Virüs Aşılarına Genel Bakış.
- Author
-
İNCEBIYIK, Adnan
- Subjects
- *
ACADEMIC medical centers , *PAPILLOMAVIRUS diseases , *DISEASE complications , *HUMAN papillomavirus vaccines , *DIAGNOSIS , *VACCINATION , *THERAPEUTICS ,TUMOR prevention ,CERVIX uteri tumors - Abstract
Cervical cancer is the second common form of cancer in women after the breast cancer. Each year, approximately 500,000 new cases of cancer worldwide recognize and nearly half of them die. After detection of the relationship between cervical cancer and human papilloma virus (HPV) studies both the prophylactic and therapeutic vaccine was accelerated. In 2006, a quadrivalent HPV 6-11-16-18 vaccine containing L1 capsid antigen, in 2007, a bivalent vaccine containing HPV 16-18 L1 capsid antigen were released. HPV vaccines produce protect antibodies against four types of HPV. Vaccines are safe and well tolerated, and leading lesions of cervical cancer and cervical cancer can be prevented. HPV vaccines are recommended in the possible range of 9-26 years, and especially before the first sexual contact. Although the prophylactic vaccine protective against cervical cancer, cervical cancer screening should be continued after vaccinations. [ABSTRACT FROM AUTHOR]
- Published
- 2012